Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation

INTRODUCTION: Patients with diabetes mellitus (DM) have augmented platelet reactivity and diminished responsiveness to clopidogrel. Ticagrelor, a more potent P2Y(12) inhibitor, is clinically superior to clopidogrel in acute coronary syndromes, although its role in chronic coronary syndromes (CCS) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcano, Ana Lucrecia, Gracida, Montserrat, Roura, Gerard, Gomez-Lara, Josep, Romaguera, Rafael, Teruel, Luis, Fuentes, Lara, Muntané-Carol, Guillem, Meroño, Oona, Sosa, Silvia Gabriela, Gómez-Hospital, Joan Antoni, Comin-Colet, Josep, Ferreiro, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722765/
https://www.ncbi.nlm.nih.gov/pubmed/36483622
http://dx.doi.org/10.3389/fcvm.2022.1057331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722765/
https://www.ncbi.nlm.nih.gov/pubmed/36483622
http://dx.doi.org/10.3389/fcvm.2022.1057331

Ejemplares similares